Optimized inhaled LNP formulation for enhanced treatment of idiopathic pulmonary fibrosis via mRNA-mediated antibody therapy
Top Cited Papers
Open Access
- 10 August 2024
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-18
Abstract
Lipid nanoparticle-assisted mRNA inhalation therapy necessitates addressing challenges such as resistance to shear force damage, mucus penetration, cellular internalization, rapid lysosomal escape, and target protein expression. Here, we introduce the innovative “LOOP” platform with a four-step workflow to develop inhaled lipid nanoparticles specifically for pulmonary mRNA delivery. iLNP-HP08LOOP featuring a high helper lipid ratio, acidic dialysis buffer, and excipient-assisted nebulization buffer, demonstrates exceptional stability and enhanced mRNA expression in the lungs. By incorporating mRNA encoding IL-11 single chain fragment variable (scFv), scFv@iLNP-HP08LOOP effectively delivers and secretes IL-11 scFv to the lungs of male mice, significantly inhibiting fibrosis. This formulation surpasses both inhaled and intravenously injected IL-11 scFv in inhibiting fibroblast activation and extracellular matrix deposition. The HP08LOOP system is also compatible with commercially available ALC0315 LNPs. Thus, the “LOOP” method presents a powerful platform for developing inhaled mRNA nanotherapeutics with potential for treating various respiratory diseases, including idiopathic pulmonary fibrosis.Keywords
Funding Information
- Gustavus and Louise Pfeiffer Research Foundation
- National Science Foundation
This publication has 60 references indexed in Scilit:
- Robust induction of neutralizing antibodies against the SARS‐CoV‐2 Delta variant after homologous Spikevax or heterologous Vaxzevria‐Spikevax vaccinationEuropean Journal of Immunology, 2022
- COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and SafetyDrug Safety, 2021
- Immunological responses to PEGylated proteins2020
- Strategies, design, and chemistry in siRNA delivery systemsAdvanced Drug Delivery Reviews, 2019
- Parenteral protein formulations: An overview of approved products within the European UnionEuropean Journal of Pharmaceutics and Biopharmaceutics, 2018
- Protein stability in pulmonary drug delivery via nebulizationAdvanced Drug Delivery Reviews, 2015
- Electrospinning of poly (ε-caprolactone-co-lactide)/Pluronic blended scaffolds for skin tissue engineeringJournal of Materials Science, 2014
- Timing of dornase alfa inhalation for cystic fibrosis2011
- Studies on aerosol delivery of plasmid DNA using a mesh nebulizerBiotechnology and Bioengineering, 2007
- The influence of surface tension on aerosols produced by medical nebulisersInternational Journal of Pharmaceutics, 1996